BR112012007888A2 - "métodos de tratamento usando anticorpos anti-ldl oxidada". - Google Patents
"métodos de tratamento usando anticorpos anti-ldl oxidada".Info
- Publication number
- BR112012007888A2 BR112012007888A2 BR112012007888A BR112012007888A BR112012007888A2 BR 112012007888 A2 BR112012007888 A2 BR 112012007888A2 BR 112012007888 A BR112012007888 A BR 112012007888A BR 112012007888 A BR112012007888 A BR 112012007888A BR 112012007888 A2 BR112012007888 A2 BR 112012007888A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- treatment
- ldl antibodies
- oxidized anti
- oxidized
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
métodos de tratamento usando anti-corpos anti-ldl oxidada. a presente invenção refere-se a métodos e composições para aumentar a sensibilidade à insulina, compreendendo a administração de anticorpos anti-ldl oxidada.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23811409P | 2009-08-28 | 2009-08-28 | |
PCT/US2010/047030 WO2011025978A2 (en) | 2009-08-28 | 2010-08-27 | Methods of treatment using anti-oxidized ldl antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012007888A2 true BR112012007888A2 (pt) | 2019-09-24 |
Family
ID=43628682
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012007888A BR112012007888A2 (pt) | 2009-08-28 | 2010-08-27 | "métodos de tratamento usando anticorpos anti-ldl oxidada". |
Country Status (12)
Country | Link |
---|---|
US (1) | US20110256134A1 (pt) |
EP (1) | EP2470210A2 (pt) |
JP (1) | JP2013503195A (pt) |
KR (1) | KR20120111724A (pt) |
CN (1) | CN102711823A (pt) |
AU (1) | AU2010286532A1 (pt) |
BR (1) | BR112012007888A2 (pt) |
CA (1) | CA2772380A1 (pt) |
IL (1) | IL218359A0 (pt) |
MX (1) | MX2012002459A (pt) |
SG (1) | SG178596A1 (pt) |
WO (1) | WO2011025978A2 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2011140498A (ru) * | 2009-03-06 | 2013-04-20 | Дженентек, Инк. | Препарат антител |
EP2788012A4 (en) * | 2011-11-11 | 2015-08-05 | Cedars Sinai Medical Center | COMPOSITIONS AND METHODS OF TREATING NURSE DISEASES |
RU2495048C1 (ru) * | 2012-04-18 | 2013-10-10 | Андрей Валентинович Исаев | Пептид, обладающий антиатеросклеротическим действием и композиция для профилактики и лечения атеросклероза сосудов |
EP3463416A1 (en) | 2016-05-31 | 2019-04-10 | CardioVax, LLC | Methods for diagnosing and treating systemic lupus erythematosus |
US10858422B2 (en) | 2016-05-31 | 2020-12-08 | Abcentra, Llc | Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody |
WO2019215300A1 (en) | 2018-05-09 | 2019-11-14 | Medirista Biotechnologies Ab | Antibodies for use in combination therapy |
WO2019232070A1 (en) * | 2018-05-29 | 2019-12-05 | Abcentra, Llc | Compositions and methods for treatment of psoriasis |
WO2022031387A1 (en) * | 2020-08-05 | 2022-02-10 | Crystal Bioscience Inc. | Anti-tigit antibody and methods of use thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030170643A1 (en) * | 1999-10-26 | 2003-09-11 | Edward Fisher | Regulation of apoB treatment and drug screening for cardiovascular and metabolic disorders or syndromes |
EP1439212B1 (en) * | 2001-10-04 | 2008-01-02 | Toray Industries, Inc. | Hydrophilic material and process for producing the same |
SE0302312D0 (sv) * | 2002-10-04 | 2003-08-27 | Forskarpatent I Syd Ab | Peptide-based passive immunization therapy for treatment of atherosclerosis |
SE0202959D0 (sv) * | 2002-10-04 | 2002-10-04 | Forskarpatent I Syd Ab Ideon | Peptide-Base passive immunization therapy for treatment of atherosclerosis |
WO2008104194A1 (en) * | 2007-02-28 | 2008-09-04 | Bioinvent International Ab | Oxidized ldl and antibodies thereto for the treatment of atheroscleroti c plaques |
-
2010
- 2010-08-27 AU AU2010286532A patent/AU2010286532A1/en not_active Abandoned
- 2010-08-27 JP JP2012527043A patent/JP2013503195A/ja active Pending
- 2010-08-27 WO PCT/US2010/047030 patent/WO2011025978A2/en active Application Filing
- 2010-08-27 MX MX2012002459A patent/MX2012002459A/es not_active Application Discontinuation
- 2010-08-27 KR KR1020127007881A patent/KR20120111724A/ko not_active IP Right Cessation
- 2010-08-27 SG SG2012014007A patent/SG178596A1/en unknown
- 2010-08-27 EP EP10812677A patent/EP2470210A2/en not_active Withdrawn
- 2010-08-27 CA CA2772380A patent/CA2772380A1/en not_active Withdrawn
- 2010-08-27 BR BR112012007888A patent/BR112012007888A2/pt not_active IP Right Cessation
- 2010-08-27 US US12/870,678 patent/US20110256134A1/en not_active Abandoned
- 2010-08-27 CN CN201080049242XA patent/CN102711823A/zh active Pending
-
2012
- 2012-02-28 IL IL218359A patent/IL218359A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2012002459A (es) | 2012-08-08 |
CN102711823A (zh) | 2012-10-03 |
KR20120111724A (ko) | 2012-10-10 |
SG178596A1 (en) | 2012-04-27 |
JP2013503195A (ja) | 2013-01-31 |
EP2470210A2 (en) | 2012-07-04 |
AU2010286532A1 (en) | 2012-04-12 |
AU2010286532A8 (en) | 2012-08-16 |
CA2772380A1 (en) | 2011-03-03 |
WO2011025978A3 (en) | 2011-04-21 |
WO2011025978A2 (en) | 2011-03-03 |
IL218359A0 (en) | 2012-04-30 |
US20110256134A1 (en) | 2011-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012007888A2 (pt) | "métodos de tratamento usando anticorpos anti-ldl oxidada". | |
UA115122C2 (uk) | Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини і cd3, що не є людським | |
EA201190217A1 (ru) | Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение | |
MX2010006823A (es) | Metodos para el tratamiento de la gota. | |
CY1121742T1 (el) | Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων | |
DK2148670T3 (da) | Titrering af tapentadol | |
CR20130016A (es) | ANTICUERPOS PEPTIDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS | |
EA201290964A1 (ru) | Пептидные конъюгаты агонистов рецептора glp-1 и их применение | |
EA201290919A1 (ru) | Индазольные соединения и их применение | |
BR112014015851A2 (pt) | proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17 | |
EA201291336A1 (ru) | Замещенные 5-фтор-1н-пиразолопиридины и их применение | |
BR112012032778A2 (pt) | "proteínas multiespecíficas e multivalentes" | |
MX2009008430A (es) | Anticuerpos anti-robo4 y sus usos. | |
EA201001639A1 (ru) | Композиции и способы их получения и применения | |
ATE511845T1 (de) | Verwendung von isothicyanat-derviaten als myelom- bekämpfende wirkstoffe | |
DK2459216T3 (da) | Immunogene sammensætninger omfattende tlr-aktivitetsmodulatorer | |
ECSP10010295A (es) | Formulacion de anticuerpo | |
MX2012007098A (es) | Derivados fenolicos y su uso farmaceutico o cosmetico. | |
MX2012007161A (es) | Derivados fenolicos y su uso farmaceutico o cosmetico. | |
AU2011274619A8 (en) | miRNA and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated BRAF pathway | |
MX356728B (es) | Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2. | |
BR112014009866A2 (pt) | formulações de anticorpos e métodos | |
BR112014005935A2 (pt) | derivados de anilina, sua preparação e sua aplicação terapêutica | |
UA113849C2 (xx) | Застосування сигма-лігандів при болю, пов'язаному з діабетом 2 типу | |
EA201171043A1 (ru) | Композиции и способы длительной терапии с применением аминопиридинов |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |